Global Small Molecule Cancer Drugs Market 2020-2026: Expected to Double in Next 6 Year Period Reaching $130 Billion, Driven by New Drug Launches & Dynamic Clinical Pipeline
September 01, 2020 04:04 ET
|
Research and Markets
Dublin, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's...
Prostate Cancer Market Study (2017-2030) in 7MM - Epidemiology Insights, Marketed & Emerging Drugs, Pipeline Activities, Access & Reimbursement Scenario, Competitive Intelligence
July 23, 2020 07:28 ET
|
Research and Markets
Dublin, July 23, 2020 (GLOBE NEWSWIRE) -- The "Prostate Cancer - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's ...
Orion Group Half-Year Financial Report 1-6/2020
July 17, 2020 05:00 ET
|
Orion Oyj
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1-6/2020 17 JULY 2020 at 12:00 noon EEST Orion Group Half-Year Financial Report 1-6/2020 This is a summary of Orion’s Half-Year...
Prostate Cancer Drug Forecast to 2028 - Big Pharma Brands Enter the Prostate Cancer Market Using Combination Strategies for mCRPC
June 10, 2020 05:18 ET
|
Research and Markets
Dublin, June 10, 2020 (GLOBE NEWSWIRE) -- The "Prostate Cancer: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering. The...
Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones
May 20, 2020 05:00 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 20 MAY 2020 at 12.00 EEST Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones Sales of Nubeqa®...
New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
May 14, 2020 00:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 14 MAY 2020 at 7.30 EEST New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival...
Orion Group Interim Report 1-3/2020
April 28, 2020 05:00 ET
|
Orion Oyj
ORION CORPORATION INTERIM REPORT 1-3/2020 28 APRIL 2020 at 12:00 noon EEST Orion Group Interim Report 1-3/2020 This is a summary of Orion’s Interim Report 1-3/2020. The complete...
Nubeqa®-lääkkeelle (darolutamidi) myyntilupa EU:ssa etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen eturauhassyövän uutena hoitona
March 30, 2020 11:15 ET
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 30.3.2020 klo 18.15 Nubeqa®-lääkkeelle (darolutamidi) myyntilupa EU:ssa etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen...
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer
March 30, 2020 11:15 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 30 MARCH 2020 at 18.15 EEST Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate...
CORRECTION: Orion Group Financial Statement Release for 2019 - wrong dividend payment date
February 05, 2020 06:20 ET
|
Orion Oyj
ORION CORPORATION FINANCIAL STATEMENT RELEASE 2019 5 FEBRUARY 2020 at 13:20 CORRECTION: Orion Group Financial Statement Release for 2019 - wrong dividend payment date Orion’s...